학술논문
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Document Type
Article
Author
Massari, Francesco; Mollica, Veronica; Fiala, Ondrej; De Giorgi, Ugo; Kucharz, Jakub; Giuseppa Vitale, Maria; Molina-Cerrillo, Javier; Facchini, Gaetano; Seront, Emmanuel; Lenci, Edoardo; Bourlon, Maria T.; Carrozza, Francesco; Pichler, Renate; Lolli, Cristian; Myint, Zin W.; Kanesvaran, Ravindran; Torniai, Mariangela; Rescigno, Pasquale; Gomez de Liaño, Alfonso; Zakopoulou, Roubini; Buti, Sebastiano; Porta, Camillo; Grande, Enrique; Santoni, Matteo
Source
European Urology Oncology; 20240101, Issue: Preprints
Subject
Language
ISSN
25889311
Abstract
We retrospectively analyzed real-world data from the ARON-1 project for patients with papillary renal cell carcinoma who received first-line immune-based combinations or tyrosine kinase inhibitors. Immune-based combinations were associated with better 1-yr and 2-yr overall survival rates, better median progression-free survival, and a better objective response rate. Immune-based combinations are the preferable option for first-line treatment in this setting.